SchuchatAHilgerTZellEFarleyMMReingoldAHarrisonLActive bacterial core surveillance of the emerging infections program network. Emerg Infect Dis2001; 7:92–9.
2.
Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2000; 49(RR-9):1–38.
3.
Notice to readers: decreased availability of pneumococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 2001; 50(36):783–4.
4.
Notice to readers: updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage—Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2001; 50(50):1140–2.
PilishviliTLexauCFarleyMMHadlerJHarrisonLHBennettNMSustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis2010; 201:32–41.
7.
ZhouFSheferAWengerJMessonnierMWangLYLopezA Economic evaluation of the routine childhood immunization program in the United States, 2009. Abstract presented at the Pediatric Academic Societies' Annual Meeting; 2012 Apr 28-May 1; Boston.
8.
Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59(9):258–61.
9.
Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged 59 months—selected U.S. regions, 2010–2011 [published erratum appears in MMWR Morb Mortal Wkly Rep 2011;60(44):1530]. MMWR Morb Mortal Wkly Rep2011; 60(43):1477–81.
10.
Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep2012; 61(21):394–5.
11.
RoushSWMurphyTV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA2007; 298:2155–63.
12.
Pub. L. No. 111-48, 124 Stat. 119 (2010).
13.
Pub. L. No. 111-52, 124 Stat. 1029 (2010).
14.
Title XXI of the Public Health Service Act (Pub. L. No. 99-660) (§2105) (42 U.S.C. 300aa-5).
15.
Pub. L. No. 67-13, 42 Stat 20, 31 U.S.C. 11.
16.
ShenAKSpinnerJRSalmonDAGellinBG. Strengthening the U.S.vaccine and immunization enterprise: the role of the National Vaccine Advisory Committee. Public Health Rep2011; 126:4–8.
17.
ReinDBHoneycuttAARojas-SmithLHerseyC. Impact of the CDC's Section 317 Immunization Grants Program funding on childhood vaccination coverage. Am J Public Health2006; 96:1548–53.
Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-5):1–22.
20.
BugenskeEStokleySKennedyADorellC. Middle school vaccination requirements and adolescent vaccination coverage. Pediatrics2012; 129:1056–63.
National, state, and urban area vaccination coverage among children aged 19–35 months—United States, 2005. MMWR Morb Mortal Wkly Rep2006; 55(36):988–93.
National Vaccine Advisory Committee. A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee. Public Health Rep2012;127Suppl 1:1–42.
KramarzPFranceEKDestefanoFBlackSBShinefieldHWardJIPopulation-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J2001; 20:410–6.
27.
Intussusception among recipients of rotavirus vaccine—United States, 1998–1999. MMWR Morb Mortal Wkly Rep 1999; 48(27):577–81.
Centers for Disease Control and Prevention (US). Pertussis (whooping cough): outbreaks [cited 2012 Sep 15]. Available from: URL: http://www.cdc.gov/pertussis/outbreaks.html
Congress of the United States Congressional Budget Office (US). Estimates for the insurance coverage provisions of the Affordable Care Act updated for the recent Supreme Court decision [cited 2012 Oct 25]. Available from: URL: http://www.cbo.gov/publication/43472